(The Center Square) – The U.S. Supreme Court, in a unanimous decision on Thursday, ruled that a cardiovascular drugmaker did not violate America’s patent laws. The ruling could allow for generic drug manufacturers to produce more without fear of patent lawsuits.
Justices on the high court ruled in favor of Hikma Pharmaceuticals in a case over whether it infringed on Amarin Pharma’s cardiovascular medication, Vascepa. The justices said Hikma Pharmaceuticals did not infringe on Amarin’s patent.
Justice Ketanji Brown Jackson said Hikma should be allowed to proceed its production of the generic drug since it got approval from the Food And Drug Adminstration. Advocates for generic drugs argued the process allows for patients to obtain necessary medication…




